Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders (Deficit) Equity

v3.22.0.1
Consolidated Statements of Stockholders (Deficit) Equity - USD ($)
$ in Thousands
Common Stock
Series B Preferred
Common Stock
Series A Preferred Stock [Member]
Common Stock
APIC
Series B Preferred
APIC
Series A Preferred Stock [Member]
APIC
Accumulated Deficit
Series B Preferred
Accumulated Deficit
Series A Preferred Stock [Member]
Accumulated Deficit
Non-Controlling InterestAccumulated Non-Controlling Stockholders'
Series B Preferred
Non-Controlling InterestAccumulated Non-Controlling Stockholders'
Series A Preferred Stock [Member]
Non-Controlling InterestAccumulated Non-Controlling Stockholders'
Preferred Stock [Member]
Series B Preferred
Preferred Stock [Member]
Series A Preferred Stock [Member]
Series B Preferred
Series A Preferred Stock [Member]
Total
Stock-based compensation     $ 0     $ 350     $ 0     $ 0 $ 0       $ 350
Stock issued under "at-the-market" offering     $ 9     3,350     0     0 0       3,359
Stock issued under "at-the-market" offering (in shares)     9,256,535                            
Series A Preferred Stock Dividends     $ 0     0     254     0 0       254
Issuance of SYN Biomics Stock     0     0     0     178 0       178
Effect of Warrant exercise price adjustment     0     880     (880)     0 0       0
Conversion of Series B Preferred Stock to Common     $ 3     3,661     (1,380)     0 $ (2,284)       0
Conversion of Series B Preferred Stock to Common (in shares)     3,186,960                   (3,665)        
Net Loss     $ 0     0     (10,043)     (73) $ 0       (10,116)
Non-controlling interest                                 (73)
Balance at Dec. 31, 2020     29     240,821     (248,094)     (2,773) 2,477       (7,540)
Balance at Dec. 31, 2019     $ 17     232,580     (235,537)     (2,878) $ 4,761       (1,057)
Balance (in shares) at Dec. 31, 2020     29,249,925                   3,973        
Balance (in shares) at Dec. 31, 2019     16,806,430                   7,638        
Stock-based compensation     $ 0     416     0     0 $ 0       416
Stock issued under "at-the-market" offering     $ 79     65,881     0     0 0       65,960
Stock issued under "at-the-market" offering (in shares)     78,685,315                            
Series A Preferred Stock Dividends     $ 0     0     24     0 0       24
Conversion of Series B Preferred Stock to Common $ 3     $ 3,971     $ (1,497)     $ 0     $ (2,477)   $ 0    
Conversion of Series B Preferred Stock to Common (in shares) 3,454,783                       (3,973)        
Net Loss     0     0     (14,267)     (1) $ 0       (14,268)
Reversal of noncontrolling interest due to return of Syn Biomics shares     0     (2,774)     0     2,774 0       0
Warrants Exercised     $ 12     8,030     0     0 0       8,042
Warrants Exercised (In shares)     11,655,747                            
Effect of Series A Preferred Stock price adjustment     $ 0     7,402     (7,402)     0 0       0
Conversion of Series A Preferred Stock to Common   $ 9     $ 12,813     $ 0     $ 0     $ 0   $ 12,822  
Conversion of Series A Preferred Stock to Common (in shares)   8,996,768                              
Non-controlling interest                                 (1)
Balance at Dec. 31, 2021     132     336,560     (271,284)     0 0       65,408
Balance at Dec. 31, 2020     $ 29     $ 240,821     $ (248,094)     $ (2,773) $ 2,477       $ (7,540)
Balance (in shares) at Dec. 31, 2021     132,042,538                            
Balance (in shares) at Dec. 31, 2020     29,249,925                   3,973